Merck & Co to buy $1bn stake in Seattle Genetics
16-09-2020
Merck KGaA wins injunction after MSD trademark suit
21-05-2020
Sanofi under fire over priority US access to COVID-19 vaccine
15-05-2020
Katherine Welles / Shutterstock.com
Merck Sharp & Dohme (MSD) is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck, Merck Sharp & Dohme, COVID-19, coronavirus, vaccine, collaboration
